The FINANCIAL — Boehringer Ingelheim, a research-based, global pharmaceutical company, announced on September 1 the licensing of Vectron Biosolutions’ expression technology platform.
This non-exclusive license agreement comes as a result of a successful joint feasibility study between the two companies in which Vectron’s proprietary genetic elements were tested for high-yield, soluble production of a protein of interest to Boehringer Ingelheim in Escherichia coli. This agreement gives Boehringer Ingelheim the right to use Vectron’s technology for both production of biopharmaceutical products from their own in-house pipeline, and as part of the Boehringer Ingelheim BioXcellence offerings in contract manufacturing, according to Boehringer Ingelheim.
”We at Boehringer Ingelheim are permanently developing and scouting novel and innovative technologies to further improve our strong microbial production platform. We believe that there is a high synergy of the Vectron Biosolutions’ technology with Boehringer Ingelheim’s own proprietary E. coli based expression systems”, said Dr. Jan Schöning, Head of Global Technology and Innovation Management Biopharmaceuticals at Boehringer Ingelheim.
“We are pleased that our technology’s potential is being recognized by one of the leading pharmaceutical companies. With Boehringer Ingelheim’s strong position in the industry, we anticipate that many future biopharmaceutical proteins will be produced using our technology“, said Dr. Trond Erik Vee Aune, CEO at Vectron Biosolutions.